Opendata, web and dolomites

SPOT SIGNED

SPOT - Synthesis of Pretargeted Oncology Theranostics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SPOT project word cloud

Explore the words cloud of the SPOT project. It provides you a very rough idea of what is the project "SPOT" about.

lost    tco    site    reaction    noise    ductal    injected    fragments    chemotherapeutic    outcome    click    ratio    small    immunological    conjugated    delivering    multivalent    tumor    np    whereby    poor    pdac    treatment    silver    lactic    hyaluronic    action    electrospraying    accumulation    gaining    undergo    intact    moieties    active    surface    alginate    additionally    nanoparticle    nps    docetaxel    exclusive    trans    ligands    healthy    subsequently    clearance    dibenzocyclooctyne    size    benefits    visualization    bioorthogonal    pancreatic    gemcitabine    xenografts    positive    tissue    drug    poly    adenocarcinoma    diagnosis    encapsulated    animal    imaging    pdca    capacities    probes    opponent    clickable    preforming    prognosis    acid    antibodies    cycloaddition    vivo    carriers    groups    overcome    ideal    ab    penetration    generation    functionalized    azide    extremely    attached    deep    cancer    shielding    dbco    zone    model    chances    contrast    tested    sulfide    tetrazine    drawbacks    pretargeted    fall    spot    cyclooctene   

Project "SPOT" data sheet

The following table provides information about the project.

Coordinator
UNIVERSIDAD COMPLUTENSE DE MADRID 

Organization address
address: AVENIDA DE SENECA 2
city: MADRID
postcode: 28040
website: http://www.ucm.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 160˙932 €
 EC max contribution 160˙932 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2022-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSIDAD COMPLUTENSE DE MADRID ES (MADRID) coordinator 160˙932.00

Map

 Project objective

To overcome size-related drawbacks of intact antibodies (Ab) for active tumor targeting, small but multivalent Ab-fragments, which fall in the “ideal tumor targeting zone”, are gaining increasing interest. However, the achieved benefits of Ab-fragments are lost when conjugated to imaging probes or drug carriers. Therefore, the SPOT action is going to focus on the generation of small Ab-fragments with highly specific targeting capacities and deep tissue penetration that are able to subsequently undergo a bioorthogonal click reaction at the tumor site. As cancer model, pancreatic ductal adenocarcinoma (PDAC), which currently still has an extremely poor prognosis, is going to be targeted. Two different click reaction will be evaluated: The cycloaddition between tetrazine and trans-cyclooctene (TCO) as well as azide and dibenzocyclooctyne (DBCO), whereby the Ab-fragments are functionalized with the TCO and DBCO groups. The opponent moieties are attached to alginate and hyaluronic acid-based ligands, which are subsequently introduced to the nanoparticle’s (NP) surface, additionally providing shielding from the immunological system. After the accumulation of the clickable Ab-fragments at the tumor site and their clearance from healthy tissue, the imaging or drug-delivering NPs with the opponent clickable moieties are injected, allowing for their exclusive accumulation at the pretargeted tumor site. For effective visualization of PDAC tissue, state-of-the-art silver sulfide NPs, with a high contrast-to-noise ratio and deep tissue imaging, are applied. The use of these NPs can be a significant step towards early PDCA diagnosis and therefore providing better chances for a positive treatment outcome. For the pretargeted drug-delivery approach, poly(lactic acid)-based NPs with encapsulated gemcitabine or docetaxel generated via electrospraying are going to be tested as a potential chemotherapeutic approach for PDAC, preforming small animal in vivo studies with PDAC xenografts.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SPOT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SPOT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

TheaTheor (2018)

Theorizing the Production of 'Comedia Nueva': The Process of Play Configuration in Spanish Golden Age Theater

Read More  

ICL CHROM (2020)

DNA interstrand crosslink repair and chromatin remodelling

Read More  

GENI (2019)

Gender, emotions and national identities: a new perspective on the abortion debates in Italy (1971-1981).

Read More